Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
153.58
+5.02 (+3.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
July 02, 2022
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development...
Via
Talk Markets
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
June 30, 2022
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal...
Via
Benzinga
7 Penny Stocks That Could Triple in 2022
June 22, 2022
Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns.
Via
InvestorPlace
Where BeiGene Stands With Analysts
May 09, 2022
Within the last quarter, BeiGene (NASDAQ:BGNE) has observed the following analyst ratings:
Via
Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
April 27, 2022
Via
Benzinga
BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer
April 19, 2022
Via
Benzinga
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
June 13, 2022
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.
Via
Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
May 13, 2022
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...
Via
Benzinga
52 Stocks Moving In Wednesday's Mid-Day Session
May 11, 2022
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247...
Via
Benzinga
Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
April 16, 2022
Deals, financings, trials and approvals in biotech in China this week.
Via
Talk Markets
99 Biggest Movers From Yesterday
May 12, 2022
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
Via
Benzinga
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
May 11, 2022
Roche isn't the only company working on an anti-TIGIT molecule.
Via
Investor's Business Daily
34 Stocks Moving in Wednesday's Pre-Market Session
May 11, 2022
Gainers Embark Technology, Inc. (NASDAQ: EMBK) rose 36.4% to $1.95 in pre-market trading. Embark Technology posted a Q1 loss of $0.04 per share.
Via
Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
May 07, 2022
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in...
Via
Talk Markets
Recap: BeiGene Q1 Earnings
May 05, 2022
BeiGene (NASDAQ:BGNE) reported its Q1 earnings results on Thursday, May 5, 2022. Here's what investors need to know about the announcement. Earnings BeiGene beat estimated earnings by 10.36%, reporting...
Via
Benzinga
HFCAA News: 128 Chinese Stocks the SEC Could Delist
May 05, 2022
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.
Via
InvestorPlace
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
April 19, 2022
Key Takeaways: InnoCare Pharma’s A-share IPO will make it the fourth innovative pharma company with shares traded in Hong Kong and on the mainland’s STAR Market...
Via
Benzinga
BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study
April 11, 2022
BeiGene Ltd (NASDAQ: BGNE) has announced results from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic...
Via
Benzinga
Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
April 11, 2022
Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company...
Via
Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
April 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Gift Chinese Regulators Just Gave Tech Stocks Like Alibaba And BeiGene
April 04, 2022
Auditing issues persist for some 270 companies trading in the U.S. But they could ease.
Via
Investor's Business Daily
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
April 01, 2022
Via
Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
March 28, 2022
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.
Via
InvestorPlace
Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.
March 25, 2022
Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way.
Via
InvestorPlace
Analyst Ratings For BeiGene
March 17, 2022
Over the past 3 months, 4 analysts have published their opinion on BeiGene (NASDAQ:BGNE) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2022
March 17, 2022
Upgrades Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,...
Via
Benzinga
10 Biggest Price Target Changes For Thursday
March 17, 2022
Keybanc cut the price target on Darden Restaurants, Inc. (NYSE: DRI) from $170 to $160. Darden shares rose 0.1% to $129.69 in pre-market trading. RBC Capital lowered Union...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.